Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas

Department of Neurological Surgery, University of California, San Francisco, California (M.C.O., M.E.I., M.Z.S., G.K., M.S., J.M.K., E.T.S., D.A., A.T.P.).
Neuro-Oncology (Impact Factor: 5.56). 12/2012; 15(2). DOI: 10.1093/neuonc/nos286
Source: PubMed


Ependymoma is the most common glial tumor of the adult spinal cord. Current consensus recommends surgical resection with gross total resection (GTR) whenever possible. We performed a comprehensive review of the literature to evaluate whether adjuvant radiotherapy after subtotal resection (STR) has any benefit.MethodsA PubMed search was performed to identify adult patients with spinal cord ependymoma who underwent surgical resection. Only patients who had clearly defined extent of resection with or without adjuvant radiotherapy were included for analysis. Kaplan-Meier and multivariate Cox regression survival analyses were performed to determine the effects of adjuvant radiotherapy on progression-free survival (PFS) and overall survival (OS).ResultsA total of 348 patients underwent surgical resection of spinal cord ependymomas, where GTR was obtained in 77.0% (268/348) of patients. Among those who received STR, 58.8% (47/80) received adjuvant radiotherapy. PFS was significantly prolonged among those who received adjuvant radiotherapy after STR (log rank; P < .001). This prolonged PFS with adjuvant radiotherapy remained significant in multivariate Cox regression analysis (STR versus STR + RT group; hazard ratio (HR) = 2.26, P = .047). By contrast, improved OS was only associated with GTR (GTR versus STR + RT group; HR = 0.07, P = .001) and benign ependymomas (HR = 0.16, P = .001).Conclusions
Surgery remains the mainstay treatment for spinal cord ependymomas, where GTR provides optimal outcomes with longest PFS and OS. Adjuvant radiotherapy prolongs PFS after STR significantly, and OS is improved by GTR and benign tumor grade only.

Full-text preview

Available from:
  • Article: Ependymomas
    [Show abstract] [Hide abstract]
    ABSTRACT: Ependymomas are the third and least common major group of gliomas after astrocytomas and oligodendrogliomas. They have distinctive histopathologic appearances and have only limited histological differential diagnoses in selected instances. They are classified by the World Health Organization into 3 grades, with grade I comprising the special subtypes of subependymoma and myxopapillary ependymoma and grade III being “anaplastic” tumors with a high local recurrence rate and a significant capacity to disseminate both in cerebrospinal fluid and hematogenously. Grade II ependymomas include classic, “cellular,” papillary, and tanycytic variants. Prognosis for each is related to patient age, tumor location (supratentorial vs posterior fossa vs spinal cord), extent of surgical resection, and histopathologic type and grade, but pathological grading is far from reliable. Molecular profiles of ependymomas are being developed but have not yet reached clinically useful status for directing therapy.
    No preview · Article · Sep 2013 · Pathology Case Reviews
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were restricted to small sample sizes, often with patients at a specific institution. Methods: Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed. Patients were all adults aged 18 years or older at the time of diagnosis. Potential prognostic clinical factors identified on univariate analysis were included in a multivariate Cox proportional hazards model with backwards selection to model progression-free survival. Results: The 282 adult ependymoma patients were equally male and female with a mean age of 43 years (range, 18-80y) at diagnosis. The majority were grade II (78%) with the tumor grade for 20 cases being reclassified on central review (half to higher grade). Tumor locations were spine (46%), infratentorial (35%), and supratentorial (19%). Tumor recurrence occurred in 26% (n = 74) of patients with a median time to progression of 14 years. A multivariate Cox proportional hazards model identified supratentorial location (P < .01), grade III (anaplastic; P < .01), and subtotal resection, followed or not by radiation (P < .01), as significantly increasing risk of early progression. Conclusions: We report findings from an ongoing, multicenter collaboration from a collection of clinically annotated adult ependymoma tumor samples demonstrating distinct predictors of progression-free survival. This unique resource provides the opportunity to better define the clinical course of ependymoma for clinical and translational studies.
    No preview · Article · Aug 2014 · Neuro-Oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Ependymomas are rare tumors of the central nervous system whose management is controversial. This population-based study of adults and children with ependymoma aims to (1) identify clinical and treatment-related factors that impact survival and (2) determine if postoperative radiotherapy (RT) can improve survival of patients with subtotal resection (STR) to levels similar to patients who had gross total resection (GTR). Methods: This retrospective population-based study evaluated 158 patients with ependymoma diagnosed between 1975-2007 in Alberta, Canada. Results: Younger patients (<7 years of age) were more likely to be diagnosed with grade III tumors compared with adults in whom grade I tumors were more common (p=0.003). Adults were more likely to have spinally located tumors compared to young children whose tumors were typically found in the brain. Overall, young children with ependymoma were more likely to die than older children or adults (p=0.001). An equivalent number of patients underwent GTR as compared with STR (48% vs 45%, respectively). Overall, older age, spinal tumor location, lower grade, and GTR were associated with improved progression free survival but only GTR was associated with significant improvement in overall survival. Median survival after STR and RT was 82 months compared with 122 months in patients who had GTR (p=0.0022). Conclusions: This is the first Canadian population-based analysis of patients with ependymoma including adults and children. Extent of resection appears to be the most important factor determining overall survival. Importantly, the addition of RT to patients initially treated with STR does not improve survival to levels similar to patients receiving GTR.
    Full-text · Article · Nov 2014 · The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.